Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +3.30%65 Forward PE Ratio is 921.28 as of Aug. 27, 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 87 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 100% on this metric.
GeneDx Holdings (NAS:WGS) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
GeneDx Holdings Forward PE Ratio Related Terms
GeneDx Holdings Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings Forward PE Ratio Chart
GeneDx Holdings Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
159.29
252.43
GeneDx Holdings Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
159.29
97.05
87.09
47.30
252.43
81.56
392.25
WGS vs NEO, CDNA, PSNL: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, GeneDx Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
GeneDx Holdings (WGS) has a Forward PE Ratio of 921.28 as of Aug. 27, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #87 out of 87 companies in the Medical Diagnostics & Research industry.
Is GeneDx Holdings' Forward PE Ratio too high?
GeneDx Holdings' current Forward PE Ratio is 921.28. The Medical Diagnostics & Research industry median Forward PE Ratio is 25.22. GeneDx Holdings' value of 921.28 is 3553% above this industry median. Based on the distribution chart, GeneDx Holdings ranks #87 out of 87 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Forward PE Ratio compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #87 out of 87 companies for Forward PE Ratio. This places GeneDx Holdings in the lower half of its industry. The industry median Forward PE Ratio is 25.22. GeneDx Holdings' value of 921.28 is 3553% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 25.22, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneDx Holdings's current Forward PE Ratio of 921.28 is 3553% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 25.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current Forward PE Ratio is 921.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Forward PE Ratio is 921.28 and 3553% above the Medical Diagnostics & Research industry median of 25.22. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Forward PE Ratio is 921.28 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Forward PE Ratio: 921.28
GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
Industry Position: 3553% above the Medical Diagnostics & Research median (#87 of 87)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
